Mablytics
Mablytics is a preclinical stage biotechnology company developing fully human monoclonal antibodies targeting a novel cell-surface protein. Their mission is to engineer better, safer immunotherapies for oncological diseases, with a focus on highly effective treatments that have low toxicity. The company's vision is to improve the lives of people diagnosed with difficult-to-treat cancers worldwide by providing targeted therapies with minimal effects on noncancerous cells.
Industries
Nr. of Employees
small (1-50)
Mablytics
San Diego, 3210 Merryfield Row, San Diego, CA 92121
Products
Preclinical immunotherapy programs targeting a novel cell-surface protein
Discovery-stage therapeutic programs that use monoclonal antibodies directed at a novel cell-surface target characterized by restricted normal-tissue expression and overexpression in certain cancers.
Preclinical immunotherapy programs targeting a novel cell-surface protein
Discovery-stage therapeutic programs that use monoclonal antibodies directed at a novel cell-surface target characterized by restricted normal-tissue expression and overexpression in certain cancers.
Services
Collaborative research and development engagements focused on discovery and preclinical advancement of targeted immunotherapies.
Advisory services related to clinical development planning, patient-centric trial methodologies, and commercialization strategy.
Collaborative research and development engagements focused on discovery and preclinical advancement of targeted immunotherapies.
Advisory services related to clinical development planning, patient-centric trial methodologies, and commercialization strategy.
Expertise Areas
- Monoclonal antibody development
- Preclinical development and pharmacology
- Assay development and analytical methods
- Proteomics and molecular biology
Key Technologies
- Fully human monoclonal antibodies
- Display-library selection technologies
- Proteomics
- Biochemical and cell-based assays